Table 1.

Resistance to challenge of mice cured by DaRT + immunomodulators and specific protection of naïve mice treated with mouse splenocytes

Challenge assay	Mouse source	Challenge cell line	N	Number of tumor-bearing mice	Tumor development (%)
	Cured by DaRT + CP + CpG + sildenafil	CT26	10	0	0
	Naïve	CT26	10	10	100
	Cured by DaRT + CP + CpG + sildenafil	DA3	8	8	100
	Naïve	DA3	10	10	100

Winn assay	Splenocytes source	Cell line	N	Number of tumor-bearing mice	Tumor development (%)
	Treated by DaRT + CP + CpG + sildenafil	CT26	12	2	17
	Naïve	CT26	12	12	100
	Treated by DaRT + CP + CpG + sildenafil	DA3	9	9	100
	Naïve	DA3	8	8	100

Mice that were cured by DaRT, sildenafil, low-dose CP and CpG (n = 18) and naïve mice (n = 20) were inoculated with 5 × 10⁵ CT26 or DA3 cells (Challenge assay). Percent of animals that developed tumors following challenge is presented. Naïve mice were injected intradermally with splenocytes from either naïve or CT26-bearing mice treated by DaRT and immunomodulators, coupled with CT26 or DA3 tumor cells in the relation of 45 Ly:1 TC (Winn assay). Percent of tumor development is presented. The presented results are based on cumulative data from two different experiments